Clinical Trials Logo

Clinical trial NCT00922259 - References

Influenza A — Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7

Citation(s)

  •   Kelly H, Carville K, Grant K, Jacoby P, Tran T, Barr I
    Estimation of influenza vaccine effectiveness from routine surveillance data. PLoS One. 2009;4(3):e5079. doi: 10.1371/journal.pone.0005079. Epub 2009 Mar 31.
  •   Roose K, Fiers W, Saelens X
    Pandemic preparedness: toward a universal influenza vaccine. Drug News Perspect. 2009 Mar;22(2):80-92. doi: 10.1358/dnp.2009.22.2.1334451. Review.
  •   Schwehm M, Wilson N
    Potential impact of pandemic influenza interventions in New Zealand: a brief modelling study. N Z Med J. 2009 Mar 13;122(1291):117-21.

Phase 1 Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H7N7 (6-2) AA ca Recombinant (A/Netherlands/219/03 (H7N7) x A/Ann Arbor/ 6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H7N7 Infection in the Event of a Pandemic

Details for clinical trial NCT00922259